ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Daiichi Sankyo, UCB Get Academic Partners

by Rick Mullin
April 14, 2014 | APPEARED IN VOLUME 92, ISSUE 15

Daiichi Sankyo and the University of California, San Francisco, have formed a drug discovery collaboration focused on neurodegenerative diseases. Daiichi Sankyo will provide its compound library to the UC San Francisco Institute for Neurodegenerative Diseases, and the partners will jointly perform high-throughput compound screening. Meanwhile, the Belgian drug company UCB has formed a research partnership with Weill Cornell Medical College. UCB will fund research programs in bone disorders, metabolic disease, and rare-genetic-variant analysis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment